Jacob Appelbaum

AML physician and CART cell researcher, using data and innovation to put patients first.

[Jacob Appelbaum @CART4AML]

@sanamloghavi Post your pre-print (or link once accepted)!

@sanamloghavi , wouldn’t you agree that megakaryocyte morphology is an important consideration for differentiating ET v pre-fibrotic MF? I view risks/Rx of these diseases differently. Nice example of what we should look for!

[Jacob Appelbaum @CART4AML]

@SCTherapeutics @2seventybio @GoHealio More options for patients with AML are desperately needed. This is an important proof of concept that a drug can be used to active a controllable CART cell therapy in patients.

[Seattle Children's Therapeutics (SCTx) @SCTherapeutics]

Early results from our PLAT-08 clinical trial in collaboration with @2seventybio showed activity against acute myeloid leukemia blasts in one patient. "This opens a new era in CAR T-cell therapy,” Dr. Jacob Appelbaum tells @GoHealio. https://t.co/A4ONeden71 #AML #ASGCT2023